New drug approvals reached an all-time high in 2023, with five gene therapies, the first CRISPR–Cas9-edited therapy and a disease-modifying Alzheimer’s drug.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
209,00 € per year
only 17,42 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Author information
Authors and Affiliations
London, UK
Melanie Senior
About this article
Cite this article
Senior, M. Fresh from the biotech pipeline: record-breaking FDA approvals.
Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02166-7
Download citation
Published: 26 February 2024
DOI: https://doi.org/10.1038/s41587-024-02166-7
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-024-02166-7